<DOC>
	<DOCNO>NCT01371435</DOCNO>
	<brief_summary>This post-marketing surveillance study design detect adverse event ( particularly clinically significant adverse drug reaction ) occur clinical setting examine factor likely affect safety efficacy paroxetine .</brief_summary>
	<brief_title>Drug Use Investigation PAXIL Tablet</brief_title>
	<detailed_description />
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Paroxetine</mesh_term>
	<criteria>Patients depression/depressed state panic disorder Patients take PAXIL since start survey Patients hypersensitivity paroxetine Patients take monoamine oxidase inhibitor ( MAOIs ) within 2 week stop treatment MAOIs Concomitant use patient take pimozide</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>